Lyell Immunopharma, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Lyell Immunopharma, Inc. (LYEL) reported Increase (Decrease) in Other Noncurrent Liabilities of $20.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-06
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was $10.00K.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was $10.00K.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$2.16M.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was -$349.00K, a 376.98% decline year-over-year.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$2.74M.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$411.00K.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$449.00K.
- Lyell Immunopharma, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$453.00K, a 112.33% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.00K 10-Q · filed 2026-08-06 | -$2.14M derived: sum of 3 quarters · filed 2026-08-06 | -$2.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-06 | -$2.15M derived: sum of 2 quarters · filed 2026-05-06 | -$2.50M derived: sum of 3 quarters · filed 2026-05-06 | -$2.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.51M derived: sum of 2 quarters · filed 2026-03-12 | -$2.62M derived: sum of 3 quarters · filed 2026-08-06 | -$2.74M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$460.00K derived: sum of 2 quarters · filed 2026-08-06 | -$572.00K 10-Q · filed 2025-11-12 | -$884.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$223.00K 10-Q · filed 2026-08-06 | -$535.00K derived: sum of 3 quarters · filed 2026-08-06 | -$409.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$112.00K 10-Q · filed 2026-05-06 | -$424.00K derived: sum of 2 quarters · filed 2026-05-06 | -$298.00K derived: sum of 3 quarters · filed 2026-05-06 | -$410.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$186.00K derived: sum of 2 quarters · filed 2026-03-12 | -$298.00K derived: sum of 3 quarters · filed 2026-03-12 | -$411.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $14.00K derived: sum of 2 quarters · filed 2025-11-12 | -$99.00K 10-Q · filed 2025-11-12 | -$211.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | -$112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$225.00K 10-Q · filed 2025-08-12 | -$337.00K derived: sum of 3 quarters · filed 2026-03-12 | -$449.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$113.00K 10-Q · filed 2025-05-13 | -$225.00K derived: sum of 2 quarters · filed 2026-03-12 | -$337.00K derived: sum of 3 quarters · filed 2026-03-12 | -$450.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$224.00K derived: sum of 2 quarters · filed 2026-03-12 | -$337.00K derived: sum of 3 quarters · filed 2026-03-12 | -$449.00K 10-K · filed 2026-03-12 |
| 2023-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$225.00K derived: sum of 2 quarters · filed 2024-11-07 | -$337.00K 10-Q · filed 2024-11-07 | -$451.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$225.00K 10-Q · filed 2024-08-07 | -$339.00K derived: sum of 3 quarters · filed 2025-03-11 | -$452.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | -$112.00K 10-Q · filed 2024-05-06 | -$226.00K derived: sum of 2 quarters · filed 2025-03-11 | -$339.00K derived: sum of 3 quarters · filed 2025-03-11 | -$452.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | -$114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$227.00K derived: sum of 2 quarters · filed 2025-03-11 | -$340.00K derived: sum of 3 quarters · filed 2025-03-11 | -$453.00K 10-K · filed 2025-03-11 |
| 2022-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$226.00K derived: sum of 2 quarters · filed 2023-11-07 | -$339.00K 10-Q · filed 2023-11-07 | -$785.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$226.00K 10-Q · filed 2023-08-08 | -$672.00K derived: sum of 3 quarters · filed 2024-02-28 | $3.45M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$113.00K 10-Q · filed 2023-05-04 | -$559.00K derived: sum of 2 quarters · filed 2024-02-28 | $3.56M derived: sum of 3 quarters · filed 2024-02-28 | $3.56M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.67M derived: sum of 2 quarters · filed 2024-02-28 | $3.67M derived: sum of 3 quarters · filed 2024-02-28 | $3.67M 10-K · filed 2024-02-28 |
| 2021-09-30 | $4.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.12M derived: sum of 2 quarters · filed 2022-11-08 | $4.12M 10-Q · filed 2022-11-08 | $4.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |